Clinical-stage cell therapy company Chimeric Therapeutics (ASX:CHM) has appointed three highly regarded cell therapy experts to the company’s Cellular Immunotherapy Scientific Advisory Board (CI-SAB).
With a growing pipeline of cellular immunotherapies Chimeric recently initiated a new Cellular Immunotherapy Scientific Advisory Board (CI-SAB) to ensure its development is informed by the latest scientific research as well as expert practical and clinical perspectives.
Dr Eric Smith – Dana-Farber Cancer Institute
Dr Smith is currently the Director of Translational Research, Immune Effector Cell Therapies, the head of the Eric Smith Lab for Synthetic Biology and Cellular Engineering at the Dana-Farber Cancer Institute and a member of the Faculty of Medicine at the Harvard Medical School in Boston, Massachusetts.
He is a highly respected translational researcher that specializes in the discovery and development of cellular immunotherapies with a focus in blood cancers.
Dr Smith utilises the latest advances in gene engineering and cellular manipulation to design and screen novel cellular therapy strategies which he then works in collaboration to rapidly advance to clinic. He spent the early part of his career in New York where he earned his MD and PhD (Genetics and Genomic Sciences) from the Mount Sinai School of Medicine, before moving to Memorial Sloan Kettering Cancer Centre (MSKCC) for his medical oncology fellowship and further research training. Dr Smith went on to serve as faculty and Director of Translational Development at the MSKCC Cellular Therapeutics Center before joining the Harvard Medical community at the Dana Farber Cancer Institute in mid-2020.
Dr Smith’s pre-clinical work has resulted in nine awarded or pending patents, multiple products stemming from his lab work have been translated to the clinic and he is an author of many seminal publications in the field.
Dr David G Maloney – Fred Hutchinson Cancer Research Centre
Dr Maloney is a renowned clinician-scientist who has been at the forefront of cellular therapy research and development. Dr Maloney has been a clinical investigator in over 15 cellular therapy clinical trials ranging from phase 1, first in human trials through to commercially approved CAR T cell therapies.
He has amassed greater than 265 publications in peer-reviewed journals and has received the Presidential Award from the International Society for Biology Therapy of Cancer (now the Society for Immunotherapy of Cancer).
He received his MD and PhD in cancer biology from Stanford University, completed a fellowship in oncology at Stanford and in 1994 joined the faculties of Fred Hutchinson Cancer Research Centre and the University of Washington where he is currently a Member in the Clinical Research Division and a Professor of Medicine in the Division of Oncology.
He is also the Medical Director for Cellular Immunotherapy and holds the Leonard and Norma Klorfine Endowed Chair for Clinical Research.
Dr Michael R Bishop – University of Chicago
Dr Bishop is a pioneer and widely recognized expert in cellular therapy research and patient care, with a focus on leukemias and lymphomas.
He has served as an investigator for multiple clinical trials investigating novel cellular immunotherapies, including phase 1 clinical trials for autologous and allogeneic CAR T and TCR products.
Dr Bishop is an active contributor to medical literature, authoring more than 200 peer-reviewed articles, in addition to more than 35 book chapters and two books on cancer treatment and research. He also serves on the editorial board of numerous scientific journals, including Biology of Blood and Marrow Transplantation.
Dr Bishop previously served as the Director of the Hematopoietic Stem Cell Transplantation Program at the University of Chicago and as a senior investigator and the clinical head of stem cell transplantation for the National Cancer Institute at the National Institutes of Health.
“We are honoured to have these outstanding individuals joining our scientific advisory board,” Chimeric’s CEO and Managing Director, Jennifer Chow, said.
“They bring deep translational expertise in cellular therapy development and are each very respected visionaries and contributors to the field. As we move into our next phase of growth we expect the insights and guidance they will bring to the table to be of great value to Chimeric.”
